![Noxxon Pharma NV](/common/images/company/EU_ALTME.png)
Noxxon Pharma NV (ALTME)
EU
NOX-E36 presents promising opportunity for development in eye diseases with a high need for well-tolerated therapies with anti-fibrotic effect Anti-fibrotic mode of action of NOX-E36 was...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0078 | 5.42420027816 | 0.1438 | 0.1592 | 0.1404 | 354382 | 0.15080739 | DE |
4 | -0.0034 | -2.1935483871 | 0.155 | 0.1648 | 0.1272 | 373210 | 0.14893044 | DE |
12 | -0.0889 | -36.9646569647 | 0.2405 | 0.27 | 0.1272 | 303784 | 0.18625173 | DE |
26 | -0.0539 | -26.2287104623 | 0.2055 | 0.436 | 0.1272 | 857090 | 0.27789847 | DE |
52 | -1.2444 | -89.1404011461 | 1.396 | 1.85 | 0.1272 | 528994 | 0.31546879 | DE |
156 | 0.1098 | 262.679425837 | 0.0418 | 5.98 | 0.0398 | 306857 | 0.39532187 | DE |
260 | 0.1098 | 262.679425837 | 0.0418 | 5.98 | 0.0398 | 306857 | 0.39532187 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.